nach oben

Cancer and Metastasis Reviews

Erschienen in:

28.05.2018

mPGES-1 and ALOX5/-15 in tumor-associated macrophages

verfasst von: Andreas Weigert, Elisabeth Strack, Ryan G. Snodgrass, Bernhard Brüne

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2-3/2018

Einloggen, um Zugang zu erhalten

Abstract

The tumor immune landscape gained considerable interest based on the knowledge that genetic aberrations in cancer cells alone are insufficient for tumor development. Macrophages are basically supporting all hallmarks of cancer and owing to their tremendous plasticity they may exert a whole spectrum of anti-tumor and pro-tumor activities. As part of the innate immune response, macrophages are armed to attack tumor cells, alone or in concert with distinct T cell subsets. However, in the tumor microenvironment, they sense nutrient and oxygen gradients, receive multiple signals, and respond to this incoming information with a phenotype shift. Often, their functional output repertoire is shifted to become tumor-supportive. Incoming and outgoing signals are chemically heterogeneous but also comprise lipid mediators. Here, we review the current understanding whereby arachidonate metabolites derived from the cyclooxygenase and lipoxygenase pathways shape the macrophage phenotype in a tumor setting. We discuss these findings in the context of cyclooxygenase-2 (COX-2) and microsomal prostaglandin E synthase-1 (mPGES-1) expression and concomitant prostaglandin E₂ (PGE₂) formation. We elaborate the multiple actions of this lipid in affecting macrophage biology, which are sensors for and generators of this lipid. Moreover, we summarize properties of 5-lipoxygenases (ALOX5) and 15-lipoxygenases (ALOX15, ALOX15B) in macrophages and clarify how these enzymes add to the role of macrophages in a dynamically changing tumor environment. This review will illustrate the potential routes how COX-2/mPGES-1 and ALOX5/-15 in macrophages contribute to the development and progression of a tumor.

Balkwill, F. R., Capasso, M., & Hagemann, T. (2012). The tumor microenvironment at a glance. Journal of Cell Science, 125, 5591–5596. https://doi.org/10.1242/jcs.116392.PubMedCrossRef

Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., et al. (2015). The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine, 21, 938–945. https://doi.org/10.1038/nm.3909.PubMedPubMedCentralCrossRef

Fridman, W. H., Zitvogel, L., Sautès-Fridman, C., & Kroemer, G. (2017). The immune contexture in cancer prognosis and treatment. Nature Reviews. Clinical Oncology, 14, 717–734. https://doi.org/10.1038/nrclinonc.2017.101.PubMedCrossRef

Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017). 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nature Immunology, 18, 255–262. https://doi.org/10.1038/ni.3682.PubMedCrossRef

Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017). Targeting neoantigens to augment antitumour immunity. Nature Reviews. Cancer, 17, 209–222. https://doi.org/10.1038/nrc.2016.154.PubMedPubMedCentralCrossRef

Lim, W. A., & June, C. H. (2017). The principles of engineering immune cells to treat cancer. Cell, 168, 724–740. https://doi.org/10.1016/j.cell.2017.01.016.PubMedPubMedCentralCrossRef

Engblom, C., Pfirschke, C., & Pittet, M. J. (2016). The role of myeloid cells in cancer therapies. Nature Reviews. Cancer, 16, 447–462. https://doi.org/10.1038/nrc.2016.54.PubMedCrossRef

Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017). Tumour-associated macrophages as treatment targets in oncology. Nature Reviews. Clinical Oncology, 14, 399–416. https://doi.org/10.1038/nrclinonc.2016.217.PubMedPubMedCentralCrossRef

Zheng, X., Turkowski, K., Mora, J., Brüne, B., Seeger, W., Weigert, A., & Savai, R. (2017). Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget, 8, 48436–48452. https://doi.org/10.18632/oncotarget.17061.PubMedPubMedCentralCrossRef

10.

Klug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., et al. (2013). Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell, 24, 589–602. https://doi.org/10.1016/j.ccr.2013.09.014.PubMedCrossRef

11.

Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., et al. (2014). Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell, 26, 623–637. https://doi.org/10.1016/j.ccell.2014.09.006.PubMedPubMedCentralCrossRef

12.

Rath, M., Müller, I., Kropf, P., Closs, E. I., & Munder, M. (2014). Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Frontiers in Immunology, 5, 532. https://doi.org/10.3389/fimmu.2014.00532.PubMedPubMedCentralCrossRef

13.

Kuang, D.-M., Zhao, Q., Peng, C., Xu, J., Zhang, J.-P., Wu, C., & Zheng, L. (2009). Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. The Journal of Experimental Medicine, 206, 1327–1337. https://doi.org/10.1084/jem.20082173.PubMedPubMedCentralCrossRef

14.

Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 10, 942–949. https://doi.org/10.1038/nm1093.PubMedCrossRef

15.

Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., et al. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 109, 6662–6667. https://doi.org/10.1073/pnas.1121623109.PubMedPubMedCentralCrossRef

16.

Barkal, A. A., Weiskopf, K., Kao, K. S., Gordon, S. R., Rosental, B., Yiu, Y. Y., et al. (2018). Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology, 19, 76–84. https://doi.org/10.1038/s41590-017-0004-z.PubMedCrossRef

17.

Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., et al. (2017). PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature, 545, 495–499. https://doi.org/10.1038/nature22396.PubMedPubMedCentralCrossRef

18.

de, P. M., Biziato, D., & Petrova, T. V. (2017). Microenvironmental regulation of tumour angiogenesis. Nature Reviews. Cancer, 17, 457–474. https://doi.org/10.1038/nrc.2017.51.CrossRef

19.

Weichand, B., Popp, R., Dziumbla, S., Mora, J., Strack, E., Elwakeel, E., et al. (2017). S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β. The Journal of Experimental Medicine, 214, 2695–2713. https://doi.org/10.1084/jem.20160392.PubMedPubMedCentralCrossRef

20.

Liu, Y., & Cao, X. (2016). Characteristics and significance of the pre-metastatic niche. Cancer Cell, 30, 668–681. https://doi.org/10.1016/j.ccell.2016.09.011.PubMedCrossRef

21.

Franklin, R. A., & Li, M. O. (2016). Ontogeny of tumor-associated macrophages and its implication in cancer regulation. Trends Cancer, 2, 20–34. https://doi.org/10.1016/j.trecan.2015.11.004.PubMedPubMedCentralCrossRef

22.

Tymoszuk, P., Evens, H., Marzola, V., Wachowicz, K., Wasmer, M.-H., Datta, S., et al. (2014). In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors. European Journal of Immunology, 44, 2247–2262. https://doi.org/10.1002/eji.201344304.PubMedCrossRef

23.

Zhu, Y., Herndon, J. M., Sojka, D. K., Kim, K.-W., Knolhoff, B. L., Zuo, C., et al. (2017). Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity, 47, 597. https://doi.org/10.1016/j.immuni.2017.08.018.PubMedCrossRef

24.

Madsen, D. H., Jürgensen, H. J., Siersbæk, M. S., Kuczek, D. E., Grey Cloud, L., Liu, S., et al. (2017). Tumor-associated macrophages derived from circulating inflammatory monocytes degrade collagen through cellular uptake. Cell Reports, 21, 3662–3671. https://doi.org/10.1016/j.celrep.2017.12.011.PubMedPubMedCentralCrossRef

25.

Franklin, R. A., Liao, W., Sarkar, A., Kim, M. V., Bivona, M. R., Liu, K., et al. (2014). The cellular and molecular origin of tumor-associated macrophages. Science, 344, 921–925. https://doi.org/10.1126/science.1252510.PubMedPubMedCentralCrossRef

26.

Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., et al. (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 475, 222–225. https://doi.org/10.1038/nature10138.PubMedPubMedCentralCrossRef

27.

Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., et al. (2014). Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell, 25, 846–859. https://doi.org/10.1016/j.ccr.2014.05.016.PubMedCrossRef

28.

Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017). Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. Journal for Immunotherapy of Cancer, 5, 53. https://doi.org/10.1186/s40425-017-0257-y.PubMedPubMedCentralCrossRef

29.

Nywening, T. M., Belt, B. A., Cullinan, D. R., Panni, R. Z., Han, B. J., Sanford, D. E., et al. (2017). Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut. https://doi.org/10.1136/gutjnl-2017-313738.

30.

Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., et al. (2017). Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell, 32, 654–668.e5. https://doi.org/10.1016/j.ccell.2017.10.005.PubMedCrossRef

31.

Biswas, S. K., & Mantovani, A. (2010). Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology, 11, 889–896. https://doi.org/10.1038/ni.1937.PubMedCrossRef

32.

Müller, E., Christopoulos, P. F., Halder, S., Lunde, A., Beraki, K., Speth, M., et al. (2017). Toll-like receptor ligands and interferon-γ synergize for induction of antitumor M1 macrophages. Frontiers in Immunology, 8, 1383. https://doi.org/10.3389/fimmu.2017.01383.PubMedPubMedCentralCrossRef

33.

Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454, 436–444. https://doi.org/10.1038/nature07205.PubMedCrossRef

34.

Cooks, T., Pateras, I. S., Jenkins, L. M., Patel, K. M., Robles, A. I., Morris, J., et al. (2018). Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nature Communications, 9, 771. https://doi.org/10.1038/s41467-018-03224-w.PubMedPubMedCentralCrossRef

35.

Cavnar, M. J., Zeng, S., Kim, T. S., Sorenson, E. C., Ocuin, L. M., Balachandran, V. P., et al. (2013). KIT oncogene inhibition drives intratumoral macrophage M2 polarization. The Journal of Experimental Medicine, 210, 2873–2886. https://doi.org/10.1084/jem.20130875.PubMedPubMedCentralCrossRef

36.

Weigert, A., Mora, J., Sekar, D., Syed, S., Brüne, B., & Killing, I. (2016). Not enough: how apoptosis hijacks tumor-associated macrophages to promote cancer progression. Advances in Experimental Medicine and Biology, 930, 205–239. https://doi.org/10.1007/978-3-319-39406-0_9. PubMedCrossRef

37.

Gregory, C. D., & Paterson, M. (2018). An apoptosis-driven 'onco-regenerative niche': roles of tumour-associated macrophages and extracellular vesicles. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. https://doi.org/10.1098/rstb.2017.0003.

38.

Biswas, S. K. (2015). Metabolic reprogramming of immune cells in cancer progression. Immunity, 43, 435–449. https://doi.org/10.1016/j.immuni.2015.09.001.PubMedCrossRef

39.

Dehne, N., Mora, J., Namgaladze, D., Weigert, A., & Brüne, B. (2017). Cancer cell and macrophage cross-talk in the tumor microenvironment. Current Opinion in Pharmacology, 35, 12–19. https://doi.org/10.1016/j.coph.2017.04.007.PubMedCrossRef

40.

Laoui, D., Movahedi, K., van Overmeire, E., van den Bossche, J., Schouppe, E., Mommer, C., et al. (2011). Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. The International Journal of Developmental Biology, 55, 861–867. https://doi.org/10.1387/ijdb.113371dl.PubMedCrossRef

41.

Olesch, C., Sha, W., Angioni, C., Sha, L. K., Açaf, E., Patrignani, P., et al. (2015). MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer. Oncotarget, 6, 10284–10296. https://doi.org/10.18632/oncotarget.3581.PubMedPubMedCentralCrossRef

42.

van Overmeire, E., Stijlemans, B., Heymann, F., Keirsse, J., Morias, Y., Elkrim, Y., et al. (2016). M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the tumor microenvironment. Cancer Research, 76, 35–42. https://doi.org/10.1158/0008-5472.CAN-15-0869.PubMedCrossRef

43.

Weigert, A., Schiffmann, S., Sekar, D., Ley, S., Menrad, H., Werno, C., et al. (2009). Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. International Journal of Cancer, 125, 2114–2121. https://doi.org/10.1002/ijc.24594.PubMedCrossRef

44.

Helm, O., Held-Feindt, J., Grage-Griebenow, E., Reiling, N., Ungefroren, H., Vogel, I., et al. (2014). Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis. International Journal of Cancer, 135, 843–861. https://doi.org/10.1002/ijc.28736.PubMedCrossRef

45.

Reinartz, S., Schumann, T., Finkernagel, F., Wortmann, A., Jansen, J. M., Meissner, W., et al. (2014). Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. International Journal of Cancer, 134, 32–42. https://doi.org/10.1002/ijc.28335.PubMedCrossRef

46.

Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., van den Bossche, J., et al. (2010). Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Research, 70, 5728–5739. https://doi.org/10.1158/0008-5472.CAN-09-4672.PubMedCrossRef

47.

Lavin, Y., Kobayashi, S., Leader, A., Amir, E.-A. D., Elefant, N., Bigenwald, C., et al. (2017). Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell, 169, 750–765.e17. https://doi.org/10.1016/j.cell.2017.04.014.PubMedPubMedCentralCrossRef

48.

Chevrier, S., Levine, J. H., Zanotelli, V. R. T., Silina, K., Schulz, D., Bacac, M., et al. (2017). An immune atlas of clear cell renal cell carcinoma. Cell, 169, 736–749.e18. https://doi.org/10.1016/j.cell.2017.04.016.PubMedPubMedCentralCrossRef

49.

Kiss, M., van Gassen, S., Movahedi, K., Saeys, Y., & Laoui, D. (2018). Myeloid cell heterogeneity in cancer: not a single cell alike. Cellular Immunology. https://doi.org/10.1016/j.cellimm.2018.02.008.

50.

Hoves, S., Ooi, C.-H., Wolter, C., Sade, H., Bissinger, S., Schmittnaegel, M., et al. (2018). Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. The Journal of Experimental Medicine, 215, 859–876. https://doi.org/10.1084/jem.20171440.PubMedPubMedCentralCrossRef

51.

Perry, C. J., Muñoz-Rojas, A. R., Meeth, K. M., Kellman, L. N., Amezquita, R. A., Thakral, D., et al. (2018). Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. The Journal of Experimental Medicine, 215, 877–893. https://doi.org/10.1084/jem.20171435.PubMedPubMedCentralCrossRef

52.

Nagahashi, M., Yamada, A., Katsuta, E., Aoyagi, T., Huang, W.-C., Terracina, K. P., et al. (2018). Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation and breast cancer metastasis. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-17-1423.

53.

Liang, J., Nagahashi, M., Kim, E. Y., Harikumar, K. B., Yamada, A., Huang, W.-C., et al. (2013). Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell, 23, 107–120. https://doi.org/10.1016/j.ccr.2012.11.013.PubMedCrossRef

54.

Seo, M.-J., & Oh, D.-K. (2017). Prostaglandin synthases: molecular characterization and involvement in prostaglandin biosynthesis. Progress in Lipid Research, 66, 50–68. https://doi.org/10.1016/j.plipres.2017.04.003.PubMedCrossRef

55.

Alexanian, A., & Sorokin, A. (2017). Cyclooxygenase 2: protein-protein interactions and posttranslational modifications. Physiological Genomics, 49, 667–681. https://doi.org/10.1152/physiolgenomics.00086.2017.PubMedCrossRef

56.

Larsson, K., & Jakobsson, P.-J. (2015). Inhibition of microsomal prostaglandin E synthase-1 as targeted therapy in cancer treatment. Prostaglandins & Other Lipid Mediators, 120, 161–165. https://doi.org/10.1016/j.prostaglandins.2015.06.002.CrossRef

57.

Sampey, A. V., Monrad, S., & Crofford, L. J. (2005). Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2. Arthritis Research & Therapy, 7, 114–117. https://doi.org/10.1186/ar1748. CrossRef

58.

Koeberle, A., & Werz, O. (2015). Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders. Biochemical Pharmacology, 98, 1–15. https://doi.org/10.1016/j.bcp.2015.06.022.PubMedCrossRef

59.

Xiao, L., Ornatowska, M., Zhao, G., Cao, H., Yu, R., Deng, J., et al. (2012). Lipopolysaccharide-induced expression of microsomal prostaglandin E synthase-1 mediates late-phase PGE2 production in bone marrow derived macrophages. PLoS One, 7, e50244. https://doi.org/10.1371/journal.pone.0050244.PubMedPubMedCentralCrossRef

60.

Díaz-Muñoz, M. D., Osma-García, I. C., Fresno, M., & Iñiguez, M. A. (2012). Involvement of PGE2 and the cAMP signalling pathway in the up-regulation of COX-2 and mPGES-1 expression in LPS-activated macrophages. The Biochemical Journal, 443, 451–461. https://doi.org/10.1042/BJ20111052.PubMedCrossRef

61.

Li, X., Yu, Y., & Funk, C. D. (2013). Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4). The FASEB Journal, 27, 4987–4997. https://doi.org/10.1096/fj.13-235333.PubMedCrossRef

62.

Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998). Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. The Journal of Clinical Investigation, 101, 890–898. https://doi.org/10.1172/JCI1112.PubMedPubMedCentralCrossRef

63.

Johann, A. M., Weigert, A., Eberhardt, W., Kuhn, A.-M., Barra, V., von Knethen, A., et al. (2008). Apoptotic cell-derived sphingosine-1-phosphate promotes HuR-dependent cyclooxygenase-2 mRNA stabilization and protein expression. Journal of Immunology, 180, 1239–1248.CrossRef

64.

Brecht, K., Weigert, A., Hu, J., Popp, R., Fisslthaler, B., Korff, T., et al. (2011). Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. The FASEB Journal, 25, 2408–2417. https://doi.org/10.1096/fj.10-179473.PubMedCrossRef

65.

Tong, M., Ding, Y., & Tai, H.-H. (2006). Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. Carcinogenesis, 27, 2170–2179. https://doi.org/10.1093/carcin/bgl053.PubMedCrossRef

66.

Kochel, T. J., & Fulton, A. M. (2015). Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. Prostaglandins & Other Lipid Mediators, 116-117, 99–103. https://doi.org/10.1016/j.prostaglandins.2014.11.003.CrossRef

67.

Arima, K., Komohara, Y., Bu, L., Tsukamoto, M., Itoyama, R., Miyake, K., et al. (2018). Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1β from activated macrophages leads to poor prognosis in pancreatic cancer. Cancer Science, 109, 462–470. https://doi.org/10.1111/cas.13467.PubMedPubMedCentralCrossRef

68.

Eruslanov, E., Kaliberov, S., Daurkin, I., Kaliberova, L., Buchsbaum, D., Vieweg, J., & Kusmartsev, S. (2009). Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. Journal of Immunology, 182, 7548–7557. https://doi.org/10.4049/jimmunol.0802358.CrossRef

69.

O'Callaghan, G., & Houston, A. (2015). Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? British Journal of Pharmacology, 172, 5239–5250. https://doi.org/10.1111/bph.13331.PubMedPubMedCentralCrossRef

70.

Ikegami, R., Sugimoto, Y., Segi, E., Katsuyama, M., Karahashi, H., Amano, F., et al. (2001). The expression of prostaglandin E receptors EP2 and EP4 and their different regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages. Journal of Immunology, 166, 4689–4696.CrossRef

71.

Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10, 181–193. https://doi.org/10.1038/nrc2809.PubMedPubMedCentralCrossRef

72.

Xia, D., Wang, D., Kim, S.-H., Katoh, H., & Dubois, R. N. (2012). Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nature Medicine, 18, 224–226. https://doi.org/10.1038/nm.2608.PubMedPubMedCentralCrossRef

73.

Kalinski, P. (2012). Regulation of immune responses by prostaglandin E2. Journal of Immunology, 188, 21–28. https://doi.org/10.4049/jimmunol.1101029.CrossRef

74.

Sha, W., Brüne, B., & Weigert, A. (2012). The multi-faceted roles of prostaglandin E2 in cancer-infiltrating mononuclear phagocyte biology. Immunobiology, 217, 1225–1232. https://doi.org/10.1016/j.imbio.2012.05.001.PubMedCrossRef

75.

Hooper, K. M., Yen, J.-H., Kong, W., Rahbari, K. M., Kuo, P.-C., Gamero, A. M., & Ganea, D. (2017). Prostaglandin E2 inhibition of IL-27 production in murine dendritic cells: a novel mechanism that involves IRF1. Journal of Immunology, 198, 1521–1530. https://doi.org/10.4049/jimmunol.1601073.CrossRef

76.

Zasłona, Z., Pålsson-McDermott, E. M., Menon, D., Haneklaus, M., Flis, E., Prendeville, H., et al. (2017). The induction of pro-IL-1β by lipopolysaccharide requires endogenous prostaglandin E2 production. Journal of Immunology, 198, 3558–3564. https://doi.org/10.4049/jimmunol.1602072.CrossRef

77.

Chen, E. P., & Smyth, E. M. (2011). COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins & Other Lipid Mediators, 96, 14–20. https://doi.org/10.1016/j.prostaglandins.2011.08.005.CrossRef

78.

Zaslona, Z., Serezani, C. H., Okunishi, K., Aronoff, D. M., & Peters-Golden, M. (2012). Prostaglandin E2 restrains macrophage maturation via E prostanoid receptor 2/protein kinase A signaling. Blood, 119, 2358–2367. https://doi.org/10.1182/blood-2011-08-374207.PubMedPubMedCentralCrossRef

79.

Lee, S. P., Serezani, C. H., Medeiros, A. I., Ballinger, M. N., & Peters-Golden, M. (2009). Crosstalk between prostaglandin E2 and leukotriene B4 regulates phagocytosis in alveolar macrophages via combinatorial effects on cyclic AMP. Journal of Immunology, 182, 530–537.CrossRef

80.

Bystrom, J., Evans, I., Newson, J., Stables, M., Toor, I., van Rooijen, N., et al. (2008). Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood, 112, 4117–4127. https://doi.org/10.1182/blood-2007-12-129767.PubMedPubMedCentralCrossRef

81.

Peters-Golden, M. (2009). Putting on the brakes: cyclic AMP as a multipronged controller of macrophage function. Science Signaling, 2, pe37. https://doi.org/10.1126/scisignal.275pe37.PubMedCrossRef

82.

Sokolowska, M., Chen, L.-Y., Liu, Y., Martinez-Anton, A., Qi, H.-Y., Logun, C., et al. (2015). Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and intracellular cyclic AMP in human macrophages. Journal of Immunology, 194, 5472–5487. https://doi.org/10.4049/jimmunol.1401343.CrossRef

83.

Nakatsuji, M., Minami, M., Seno, H., Yasui, M., Komekado, H., Higuchi, S., et al. (2015). EP4 receptor-associated protein in macrophages ameliorates colitis and colitis-associated tumorigenesis. PLoS Genetics, 11, e1005542. https://doi.org/10.1371/journal.pgen.1005542.PubMedPubMedCentralCrossRef

84.

Ruffell, D., Mourkioti, F., Gambardella, A., Kirstetter, P., Lopez, R. G., Rosenthal, N., & Nerlov, C. (2009). A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proceedings of the National Academy of Sciences of the United States of America, 106, 17475–17480. https://doi.org/10.1073/pnas.0908641106.PubMedPubMedCentralCrossRef

85.

Luan, B., Yoon, Y.-S., Le Lay, J., Kaestner, K. H., Hedrick, S., & Montminy, M. (2015). CREB pathway links PGE2 signaling with macrophage polarization. Proceedings of the National Academy of Sciences of the United States of America, 112, 15642–15647. https://doi.org/10.1073/pnas.1519644112.PubMedPubMedCentralCrossRef

86.

Qian, X., Zhang, J., & Liu, J. (2011). Tumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP/PKA signaling pathway. The Journal of Biological Chemistry, 286, 2111–2120. https://doi.org/10.1074/jbc.M110.154971.PubMedCrossRef

87.

Hangai, S., Ao, T., Kimura, Y., Matsuki, K., Kawamura, T., Negishi, H., et al. (2016). PGE2 induced in and released by dying cells functions as an inhibitory DAMP. Proceedings of the National Academy of Sciences of the United States of America, 113, 3844–3849. https://doi.org/10.1073/pnas.1602023113.PubMedPubMedCentralCrossRef

88.

Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., et al. (2015). Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell, 162, 1257–1270. https://doi.org/10.1016/j.cell.2015.08.015.PubMedPubMedCentralCrossRef

89.

Prima, V., Kaliberova, L. N., Kaliberov, S., Curiel, D. T., & Kusmartsev, S. (2017). COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proceedings of the National Academy of Sciences of the United States of America, 114, 1117–1122. https://doi.org/10.1073/pnas.1612920114.PubMedPubMedCentralCrossRef

90.

Sasaki, Y., Kamei, D., Ishikawa, Y., Ishii, T., Uematsu, S., Akira, S., et al. (2012). Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis. Oncogene, 31, 2943–2952. https://doi.org/10.1038/onc.2011.472.PubMedCrossRef

91.

Eruslanov, E., Daurkin, I., Ortiz, J., Vieweg, J., & Kusmartsev, S. (2010). Pivotal advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells. Journal of Leukocyte Biology, 88, 839–848. https://doi.org/10.1189/jlb.1209821.PubMedCrossRef

92.

Janakiram, N. B., Mohammed, A., Bryant, T., Ritchie, R., Stratton, N., Jackson, L., et al. (2017). Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+mice. Immunology, 152, 36–51. https://doi.org/10.1111/imm.12746.PubMedPubMedCentralCrossRef

93.

Gregory, C. D., & Pound, J. D. (2011). Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. The Journal of Pathology, 223, 177–194. https://doi.org/10.1002/path.2792.PubMedCrossRef

94.

Kamata, H., Hosono, K., Suzuki, T., Ogawa, Y., Kubo, H., Katoh, H., et al. (2010). mPGES-1-expressing bone marrow-derived cells enhance tumor growth and angiogenesis in mice. Biomedicine & Pharmacotherapy, 64, 409–416. https://doi.org/10.1016/j.biopha.2010.01.017.CrossRef

95.

Rong, X., Huang, B., Qiu, S., Li, X., He, L., & Peng, Y. (2016). Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation. Oncotarget, 7, 83976–83986. https://doi.org/10.18632/oncotarget.6930.PubMedPubMedCentralCrossRef

96.

Nandi, P., Girish, G. V., Majumder, M., Xin, X., Tutunea-Fatan, E., & Lala, P. K. (2017). PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells. BMC Cancer, 17, 11. https://doi.org/10.1186/s12885-016-3018-2.PubMedPubMedCentralCrossRef

97.

Gan, L., Qiu, Z., Huang, J., Li, Y., Huang, H., Xiang, T., et al. (2016). Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway. International Journal of Biological Sciences, 12, 1533–1543. https://doi.org/10.7150/ijbs.15943.PubMedPubMedCentralCrossRef

98.

Khan, K. M. F., Kothari, P., Du, B., Dannenberg, A. J., & Falcone, D. J. (2012). Matrix metalloproteinase-dependent microsomal prostaglandin E synthase-1 expression in macrophages: role of TNF-α and the EP4 prostanoid receptor. Journal of Immunology, 188, 1970–1980. https://doi.org/10.4049/jimmunol.1102383.CrossRef

99.

Rådmark, O., & Samuelsson, B. (2009). 5-Lipoxygenase: mechanisms of regulation. Journal of Lipid Research, 50(Suppl), S40–S45. https://doi.org/10.1194/jlr.R800062-JLR200.PubMedPubMedCentralCrossRef

100.

Yokomizo, T., Kato, K., Terawaki, K., Izumi, T., & Shimizu, T. (2000). A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. The Journal of Experimental Medicine, 192, 421–432.PubMedPubMedCentralCrossRef

101.

Yokomizo, T., Kato, K., Hagiya, H., Izumi, T., & Shimizu, T. (2001). Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. The Journal of Biological Chemistry, 276, 12454–12459. https://doi.org/10.1074/jbc.M011361200.PubMedCrossRef

102.

Ogasawara, H., Ishii, S., Yokomizo, T., Kakinuma, T., Komine, M., Tamaki, K., et al. (2002). Characterization of mouse cysteinyl leukotriene receptors mCysLT1 and mCysLT2: differential pharmacological properties and tissue distribution. The Journal of Biological Chemistry, 277, 18763–18768. https://doi.org/10.1074/jbc.M109447200.PubMedCrossRef

103.

Heise, C. E., O'Dowd, B. F., Figueroa, D. J., Sawyer, N., Nguyen, T., Im, D. S., et al. (2000). Characterization of the human cysteinyl leukotriene 2 receptor. The Journal of Biological Chemistry, 275, 30531–30536. https://doi.org/10.1074/jbc.M003490200.PubMedCrossRef

104.

Lötzer, K., Funk, C. D., & Habenicht, A. J. R. (2005). The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochimica et Biophysica Acta, 1736, 30–37. https://doi.org/10.1016/j.bbalip.2005.07.001.PubMedCrossRef

105.

Dahlén, S.-E. (2006). Treatment of asthma with antileukotrienes: first line or last resort therapy? European Journal of Pharmacology, 533, 40–56. https://doi.org/10.1016/j.ejphar.2005.12.070.PubMedCrossRef

106.

Hammamieh, R., Sumaida, D., Zhang, X., Das, R., & Jett, M. (2007). Control of the growth of human breast cancer cells in culture by manipulation of arachidonate metabolism. BMC Cancer, 7, 138. https://doi.org/10.1186/1471-2407-7-138.PubMedPubMedCentralCrossRef

107.

Barresi, V., Grosso, M., Vitarelli, E., Tuccari, G., & Barresi, G. (2007). 5-Lipoxygenase is coexpressed with Cox-2 in sporadic colorectal cancer: a correlation with advanced stage. Diseases of the Colon and Rectum, 50, 1576–1584. https://doi.org/10.1007/s10350-007-0311-9.PubMedCrossRef

108.

Matsuyama, M., Hayama, T., Funao, K., Kawahito, Y., Sano, H., Takemoto, Y., et al. (2007). Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Oncology Reports, 18, 99–104.PubMed

109.

Sarveswaran, S., Varma, N., Morisetty, S., & Ghosh, J. (2016). Inhibition of 5-lipoxygenase downregulates stemness and kills prostate cancer stem cells by triggering apoptosis via activation of c-Jun N-terminal kinase*. Oncotarget. https://doi.org/10.18632/oncotarget.13422.

110.

Ghosh, J., & Myers, C. E. (1998). Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 95, 13182–13187.PubMedPubMedCentralCrossRef

111.

Meng, Z., Cao, R., Yang, Z., Liu, T., Wang, Y., & Wang, X. (2013). Inhibitor of 5-lipoxygenase, zileuton, suppresses prostate cancer metastasis by upregulating E-cadherin and paxillin. Urology, 82, 1452.e7–1452.14. https://doi.org/10.1016/j.urology.2013.08.060.CrossRef

112.

Sarveswaran, S., Chakraborty, D., Chitale, D., Sears, R., & Ghosh, J. (2015). Inhibition of 5-lipoxygenase selectively triggers disruption of c-Myc signaling in prostate cancer cells. The Journal of Biological Chemistry, 290, 4994–5006. https://doi.org/10.1074/jbc.M114.599035.PubMedCrossRef

113.

Shen, J., Li, W. X., Xiao, Z. G., Zhang, L., Li, M. X., Li, L. F., et al. (2016). The co-regulatory role of 5-lipoxygenase and cyclooxygenase-2 in the carcinogenesis and their promotion by cigarette smoking in colons. Current Medicinal Chemistry, 23, 1131–1138.PubMedCrossRef

114.

Moore, G. Y., & Pidgeon, G. P. (2017). Cross-talk between cancer cells and the tumour microenvironment: the role of the 5-lipoxygenase pathway. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18020236.

115.

Boger, P. C., Shutt, J. D., Neale, J. R., Wilson, S. J., Bateman, A. C., Holloway, J. W., et al. (2012). Increased expression of the 5-lipoxygenase pathway and its cellular localization in Barrett's adenocarcinoma. Histopathology, 61, 509–517. https://doi.org/10.1111/j.1365-2559.2012.04258.x.PubMedCrossRef

116.

Reinartz, S., Finkernagel, F., Adhikary, T., Rohnalter, V., Schumann, T., Schober, Y., et al. (2016). A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biology, 17, 108. https://doi.org/10.1186/s13059-016-0956-6.PubMedPubMedCentralCrossRef

117.

Brenner, C., Galluzzi, L., Kepp, O., & Kroemer, G. (2013). Decoding cell death signals in liver inflammation. Journal of Hepatology, 59, 583–594. https://doi.org/10.1016/j.jhep.2013.03.033.PubMedCrossRef

118.

Poczobutt, J. M., Gijon, M., Amin, J., Hanson, D., Li, H., Walker, D., et al. (2013). Eicosanoid profiling in an orthotopic model of lung cancer progression by mass spectrometry demonstrates selective production of leukotrienes by inflammatory cells of the microenvironment. PLoS One, 8, e79633. https://doi.org/10.1371/journal.pone.0079633.PubMedPubMedCentralCrossRef

119.

Poczobutt, J. M., De, S., Yadav, V. K., Nguyen, T. T., Li, H., Sippel, T. R., et al. (2016). Expression profiling of macrophages reveals multiple populations with distinct biological roles in an immunocompetent orthotopic model of lung cancer. Journal of Immunology, 196, 2847–2859. https://doi.org/10.4049/jimmunol.1502364.CrossRef

120.

Wen, Z., Liu, H., Li, M., Li, B., Gao, W., Shao, Q., et al. (2015). Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration. Oncogene, 34, 1241–1252. https://doi.org/10.1038/onc.2014.85.PubMedCrossRef

121.

Cheon, E. C., Strouch, M. J., Krantz, S. B., Heiferman, M. J., & Bentrem, D. J. (2012). Genetic deletion of 5-lipoxygenase increases tumor-infiltrating macrophages in Apc(Δ468) mice. Journal of Gastrointestinal Surgery, 16, 389–393. https://doi.org/10.1007/s11605-011-1761-x.PubMedCrossRef

122.

Gounaris, E., Heiferman, M. J., Heiferman, J. R., Shrivastav, M., Vitello, D., Blatner, N. R., et al. (2015). Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation. PLoS One, 10, e0121402. https://doi.org/10.1371/journal.pone.0121402.PubMedPubMedCentralCrossRef

123.

Nosaka, T., Baba, T., Tanabe, Y., Sasaki, S., Nishimura, T., Imamura, Y., et al. (2018). Alveolar macrophages drive hepatocellular carcinoma lung metastasis by generating leukotriene B4. Journal of Immunology. https://doi.org/10.4049/jimmunol.1700544.

124.

Kitamura, T., Qian, B.-Z., Soong, D., Cassetta, L., Noy, R., Sugano, G., et al. (2015). CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. The Journal of Experimental Medicine, 212, 1043–1059. https://doi.org/10.1084/jem.20141836.PubMedPubMedCentralCrossRef

125.

Poczobutt, J. M., Nguyen, T. T., Hanson, D., Li, H., Sippel, T. R., Weiser-Evans, Mary, C. M., et al. (2016). Deletion of 5-lipoxygenase in the tumor microenvironment promotes lung cancer progression and metastasis through regulating T cell recruitment. Journal of Immunology, 196, 891–901. https://doi.org/10.4049/jimmunol.1501648.CrossRef

126.

Ringleb, J., Strack, E., Angioni, C., Geisslinger, G., Steinhilber, D., Weigert, A., & Brüne, B. (2018). Apoptotic cancer cells suppress 5-lipoxygenase in tumor-associated macrophages. Journal of Immunology, 200, 857–868. https://doi.org/10.4049/jimmunol.1700609.CrossRef

127.

Rossi, A., Pergola, C., Koeberle, A., Hoffmann, M., Dehm, F., Bramanti, P., et al. (2010). The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages. British Journal of Pharmacology, 161, 555–570. https://doi.org/10.1111/j.1476-5381.2010.00930.x.PubMedPubMedCentralCrossRef

128.

Park, S.-W., Heo, D.-S., & Sung, M.-W. (2012). The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells. Cellular Oncology (Dordrecht), 35, 1–8. https://doi.org/10.1007/s13402-011-0051-7. CrossRef

129.

Weigert, A., von, K. A., Fuhrmann, D., Dehne, N., & Brüne, B. (2018). Redox-signals and macrophage biology (for the upcoming issue of molecular aspects of medicine on signaling by reactive oxygen species). Molecular Aspects of Medicine. https://doi.org/10.1016/j.mam.2018.01.003.

130.

Edelman, M. J., Watson, D., Wang, X., Morrison, C., Kratzke, R. A., Jewell, S., et al. (2008). Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy—Cancer and Leukemia Group B Trial 30203. Journal of Clinical Oncology, 26, 848–855. https://doi.org/10.1200/JCO.2007.13.8081.PubMedCrossRef

131.

Kuhn, H., Banthiya, S., & van Leyen, K. (2015). Mammalian lipoxygenases and their biological relevance. Biochimica et Biophysica Acta, 1851, 308–330. https://doi.org/10.1016/j.bbalip.2014.10.002.PubMedCrossRef

132.

Ivanov, I., Kuhn, H., & Structural, H. D. (2015). functional biology of arachidonic acid 15-lipoxygenase-1 (ALOX15). Gene, 573, 1–32. https://doi.org/10.1016/j.gene.2015.07.073. PubMedCrossRef

133.

Wuest, S. J. A., Crucet, M., Gemperle, C., Loretz, C., & Hersberger, M. (2012). Expression and regulation of 12/15-lipoxygenases in human primary macrophages. Atherosclerosis, 225, 121–127. https://doi.org/10.1016/j.atherosclerosis.2012.07.022.PubMedCrossRef

134.

Ackermann, J. A., Hofheinz, K., Zaiss, M. M., & Krönke, G. (2017). The double-edged role of 12/15-lipoxygenase during inflammation and immunity. Biochimica et Biophysica Acta, 1862, 371–381. https://doi.org/10.1016/j.bbalip.2016.07.014.PubMedCrossRef

135.

Bender, G., Schexnaydre, E. E., Murphy, R. C., Uhlson, C., & Newcomer, M. E. (2016). Membrane-dependent activities of human 15-LOX-2 and its murine counterpart: implications for murine models of atherosclerosis. The Journal of Biological Chemistry, 291, 19413–19424. https://doi.org/10.1074/jbc.M116.741454.PubMedPubMedCentralCrossRef

136.

Hammond, V. J., & O'Donnell, V. B. (2012). Esterified eicosanoids: generation, characterization and function. Biochimica et Biophysica Acta, 1818, 2403–2412. https://doi.org/10.1016/j.bbamem.2011.12.013.PubMedCrossRef

137.

O'Donnell, V. B., & Murphy, R. C. (2012). New families of bioactive oxidized phospholipids generated by immune cells: identification and signaling actions. Blood, 120, 1985–1992. https://doi.org/10.1182/blood-2012-04-402826.PubMedPubMedCentralCrossRef

138.

Morgan, A. H., Hammond, V. J., Sakoh-Nakatogawa, M., Ohsumi, Y., Thomas, C. P., Blanchet, F., et al. (2015). A novel role for 12/15-lipoxygenase in regulating autophagy. Redox Biology, 4, 40–47. https://doi.org/10.1016/j.redox.2014.11.005.PubMedCrossRef

139.

Kagan, V. E., Mao, G., Qu, F., Angeli, J. P. F., Doll, S., Croix, C. S., et al. (2017). Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nature Chemical Biology, 13, 81–90. https://doi.org/10.1038/nchembio.2238.PubMedCrossRef

140.

Ou, Y., Wang, S.-J., Li, D., Chu, B., & Gu, W. (2016). Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proceedings of the National Academy of Sciences of the United States of America, 113, E6806–E6812. https://doi.org/10.1073/pnas.1607152113.PubMedPubMedCentralCrossRef

141.

Shureiqi, I., Jiang, W., Zuo, X., Wu, Y., Stimmel, J. B., Leesnitzer, L. M., et al. (2003). The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 9968–9973. https://doi.org/10.1073/pnas.1631086100.PubMedPubMedCentralCrossRef

142.

Su, C. G., Wen, X., Bailey, S. T., Jiang, W., Rangwala, S. M., Keilbaugh, S. A., et al. (1999). A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. The Journal of Clinical Investigation, 104, 383–389. https://doi.org/10.1172/JCI7145.PubMedPubMedCentralCrossRef

143.

Tanaka, T., Kohno, H., Yoshitani, S., Takashima, S., Okumura, A., Murakami, A., & Hosokawa, M. (2001). Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Research, 61, 2424–2428.PubMed

144.

Zuo, X., Wu, Y., Morris, J. S., Stimmel, J. B., Leesnitzer, L. M., Fischer, S. M., et al. (2006). Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene, 25, 1225–1241. https://doi.org/10.1038/sj.onc.1209160.PubMedPubMedCentralCrossRef

145.

Powell, W. S., & Rokach, J. (2015). Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. Biochimica et Biophysica Acta, 1851, 340–355. https://doi.org/10.1016/j.bbalip.2014.10.008.PubMedCrossRef

146.

Marcheselli, V. L., Hong, S., Lukiw, W. J., Tian, X. H., Gronert, K., Musto, A., et al. (2003). Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. The Journal of Biological Chemistry, 278, 43807–43817. https://doi.org/10.1074/jbc.M305841200.PubMedCrossRef

147.

Kumar, N., Gupta, G., Anilkumar, K., Fatima, N., Karnati, R., Reddy, G. V., et al. (2016). 15-Lipoxygenase metabolites of α-linolenic acid, 13-(S)-HPOTrE and 13-(S)-HOTrE, mediate anti-inflammatory effects by inactivating NLRP3 inflammasome. Scientific Reports, 6, 31649. https://doi.org/10.1038/srep31649.PubMedPubMedCentralCrossRef

148.

Pham, H., Banerjee, T., & Ziboh, V. A. (2004). Suppression of cyclooxygenase-2 overexpression by 15S-hydroxyeicosatrienoic acid in androgen-dependent prostatic adenocarcinoma cells. International Journal of Cancer, 111, 192–197. https://doi.org/10.1002/ijc.20245.PubMedCrossRef

149.

Klil-Drori, A. J., & Ariel, A. (2013). 15-Lipoxygenases in cancer: a double-edged sword? Prostaglandins & Other Lipid Mediators, 106, 16–22. https://doi.org/10.1016/j.prostaglandins.2013.07.006.CrossRef

150.

Moreno, J. J. (2009). New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochemical Pharmacology, 77, 1–10. https://doi.org/10.1016/j.bcp.2008.07.033.PubMedCrossRef

151.

Kang, K.-H., Ling, T.-Y., Liou, H.-H., Huang, Y.-K., Hour, M.-J., Liou, H.-C., & Fu, W.-M. (2013). Enhancement role of host 12/15-lipoxygenase in melanoma progression. European Journal of Cancer, 49, 2747–2759. https://doi.org/10.1016/j.ejca.2013.03.030.PubMedCrossRef

152.

Pidgeon, G. P., Kandouz, M., Meram, A., & Honn, K. V. (2002). Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Research, 62, 2721–2727.PubMed

153.

Chabane, N., Zayed, N., Benderdour, M., Martel-Pelletier, J., Pelletier, J.-P., Duval, N., & Fahmi, H. (2009). Human articular chondrocytes express 15-lipoxygenase-1 and -2: potential role in osteoarthritis. Arthritis Research & Therapy, 11, R44. https://doi.org/10.1186/ar2652.CrossRef

154.

Chiurchiù, V., Leuti, A., & Maccarrone, M. (2018). Bioactive lipids and chronic inflammation: managing the fire within. Frontiers in Immunology, 9, 38. https://doi.org/10.3389/fimmu.2018.00038.PubMedPubMedCentralCrossRef

155.

Wu, R.-F., Huang, Z.-X., Ran, J., Dai, S.-J., Lin, D.-C., Ng, T.-W., et al. (2018). Lipoxin A4 suppresses estrogen-induced epithelial-mesenchymal transition via ALXR-dependent manner in endometriosis. Reproductive Sciences, 25, 566–578. https://doi.org/10.1177/1933719117718271.PubMedCrossRef

156.

Schnittert, J., Heinrich, M. A., Kuninty, P. R., Storm, G., & Prakash, J. (2018). Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer. Cancer Letters, 420, 247–258. https://doi.org/10.1016/j.canlet.2018.01.072.PubMedCrossRef

157.

Serhan, C. N., Chiang, N., Dalli, J., & Levy, B. D. (2014). Lipid mediators in the resolution of inflammation. Cold Spring Harbor Perspectives in Biology, 7, a016311. https://doi.org/10.1101/cshperspect.a016311.PubMedCrossRef

158.

Zhang, Q., Zhu, B., & Li, Y. (2017). Resolution of cancer-promoting inflammation: a new approach for anticancer therapy. Frontiers in Immunology, 8, 71. https://doi.org/10.3389/fimmu.2017.00071.PubMedPubMedCentralCrossRef

159.

Sulciner, M. L., Serhan, C. N., Gilligan, M. M., Mudge, D. K., Chang, J., Gartung, A., et al. (2018). Resolvins suppress tumor growth and enhance cancer therapy. The Journal of Experimental Medicine, 215, 115–140. https://doi.org/10.1084/jem.20170681.PubMedPubMedCentralCrossRef

160.

Tian, R., Zuo, X., Jaoude, J., Mao, F., Colby, J., & Shureiqi, I. (2017). ALOX15 as a suppressor of inflammation and cancer: lost in the link. Prostaglandins & Other Lipid Mediators, 132, 77–83. https://doi.org/10.1016/j.prostaglandins.2017.01.002.CrossRef

161.

Chung, W., Eum, H. H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., et al. (2017). Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nature Communications, 8, 15081. https://doi.org/10.1038/ncomms15081.PubMedPubMedCentralCrossRef

162.

Zuo, X., Peng, Z., Wu, Y., Moussalli, M. J., Yang, X. L., Wang, Y., et al. (2012). Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice. Journal of the National Cancer Institute, 104, 709–716. https://doi.org/10.1093/jnci/djs187.PubMedPubMedCentralCrossRef

163.

Deguchi, A., Xing, S. W., Shureiqi, I., Yang, P., Newman, R. A., Lippman, S. M., et al. (2005). Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells. Cancer Research, 65, 8442–8447. https://doi.org/10.1158/0008-5472.CAN-05-1109.PubMedCrossRef

164.

Mao, F., Xu, M., Zuo, X., Yu, J., Xu, W., Moussalli, M. J., et al. (2015). 15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6/STAT3 signaling pathway. The FASEB Journal, 29, 2359–2370. https://doi.org/10.1096/fj.14-264515.PubMedPubMedCentralCrossRef

165.

Moussalli, M. J., Wu, Y., Zuo, X., Yang, X. L., Wistuba, I. I., Raso, M. G., et al. (2011). Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion. Cancer Prevention Research (Philadelphia, Pa.), 4, 1961–1972. https://doi.org/10.1158/1940-6207.CAPR-10-0280.CrossRef

166.

Schif-Zuck, S., Gross, N., Assi, S., Rostoker, R., Serhan, C. N., & Ariel, A. (2011). Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. European Journal of Immunology, 41, 366–379. https://doi.org/10.1002/eji.201040801.PubMedCrossRef

167.

Uderhardt, S., Herrmann, M., Oskolkova, O. V., Aschermann, S., Bicker, W., Ipseiz, N., et al. (2012). 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity, 36, 834–846. https://doi.org/10.1016/j.immuni.2012.03.010.PubMedCrossRef

168.

Kwon, H.-J., Kim, S.-N., Kim, Y.-A., & Lee, Y.-H. (2016). The contribution of arachidonate 15-lipoxygenase in tissue macrophages to adipose tissue remodeling. Cell Death & Disease, 7, e2285. https://doi.org/10.1038/cddis.2016.190.CrossRef

169.

Wang. (2010). Downregulation of 15-lipoxygenase 2 by glucocorticoid receptor in prostate cancer cells. International Journal of Oncology. https://doi.org/10.3892/ijo_00000641.

170.

Schneider, C., & Pozzi, A. (2011). Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Reviews, 30, 277–294. https://doi.org/10.1007/s10555-011-9310-3.PubMedPubMedCentralCrossRef

171.

Abrial, C., Grassin-Delyle, S., Salvator, H., Brollo, M., Naline, E., & Devillier, P. (2015). 15-Lipoxygenases regulate the production of chemokines in human lung macrophages. British Journal of Pharmacology, 172, 4319–4330. https://doi.org/10.1111/bph.13210.PubMedPubMedCentralCrossRef

172.

Ruffell, B., Affara, N. I., & Coussens, L. M. (2012). Differential macrophage programming in the tumor microenvironment. Trends in Immunology, 33, 119–126. https://doi.org/10.1016/j.it.2011.12.001.PubMedPubMedCentralCrossRef

173.

Daurkin, I., Eruslanov, E., Stoffs, T., Perrin, G. Q., Algood, C., Gilbert, S. M., et al. (2011). Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Research, 71, 6400–6409. https://doi.org/10.1158/0008-5472.CAN-11-1261.PubMedCrossRef

Titel: mPGES-1 and ALOX5/-15 in tumor-associated macrophages
verfasst von: Andreas Weigert
Elisabeth Strack
Ryan G. Snodgrass
Bernhard Brüne
Publikationsdatum: 28.05.2018
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2-3/2018
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-018-9731-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

mPGES-1 and ALOX5/-15 in tumor-associated macrophages

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2-3/2018

Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond

Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications

Thrombospondin-1 interactions regulate eicosanoid metabolism and signaling in cancer-related inflammation

Role of autotaxin in cancer stem cells

Bioanalytical insights into the association between eicosanoids and pathogenesis of hepatocellular carcinoma

Preface

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie